Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint.

@article{Jankowski2008Cyclooxygenase2II,
  title={Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint.},
  author={Janusz Jankowski and Richard Hunt},
  journal={Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology},
  year={2008},
  volume={17 8},
  pages={1858-61}
}
Aspirin is the best chemoprevention agent for colorectal cancer risk reduction despite the fact that the evidence for a decrease in mortality is weak. The cyclooxygenase-2 selective agents (COXIBS) have an efficacy similar to that of aspirin for most gastrointestinal (GI) lesions but not esophagus. Specifically, there are beneficial short term effects of COXIBs on the risk of colorectal adenoma as shown in the Approve, PreSAP, and APC studies. However, there is still an increased risk of upper… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

COX-2 Inhibitors and Gastric Cancer

Gastroenterology research and practice • 2014

PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology • 2010
View 2 Excerpts

Similar Papers

Loading similar papers…